Chemistry:25T2-NBOMe
From HandWiki
25T2-NBOMe, also known as N-(2-methoxybenzyl)-4-ethylthio-2,5-dimethoxyphenethylamine, is a serotonergic psychedelic of the 25-NB (NBOMe) family.[1][2][3][4][5][6] It is the NBOMe analogue of 2C-T-2.[1][2][3][4][5][6]
Use and effects
25T2-NBOMe's reported active dose range in humans has been described as 100 to 1,000 μg, with a typical dose estimate of 500 μg.[7] The route is sublingual administration.[7]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 2,200 |
| 5-HT1B | ND |
| 5-HT1D | ND |
| 5-HT1E | ND |
| 5-HT1F | ND |
| 5-HT2A | 0.56–0.6 (Ki) 4.37–100 (EC50) 38–81% (Emax) |
| 5-HT2B | 0.85 (Ki) 40 (EC50) 31% (Emax) |
| 5-HT2C | 6.5 (Ki) 12.0 (EC50) 103% (Emax) |
| 5-HT3 | ND |
| 5-HT4 | ND |
| 5-HT5A | ND |
| 5-HT6 | 84.9 |
| 5-HT7 | ND |
| α1A | 550 |
| α1B, α1D | ND |
| α2A | 450 |
| α2B, α2C | ND |
| β1–β3 | ND |
| D1 | 7,700 |
| D2 | 1,600 |
| D3 | 3,000 |
| D4, D5 | ND |
| H1 | 490 |
| H2–H4 | ND |
| M1–M5 | ND |
| I1 | ND |
| σ1, σ2 | ND |
| ORs | ND |
| TAAR1 | 4,200 (Ki) (mouse) 350 (Ki) (rat) 2,900 (EC50) (mouse) 930 (EC50) (rat) >10,000 (EC50) (human) 30% (Emax) (mouse) 24% (Emax) (rat) |
| SERT | 5,000 (Ki) 20,000 (IC50) ND (EC50) |
| NET | 5,900 (Ki) 25,000 (IC50) ND (EC50) |
| DAT | 8,600 (Ki) 67,000 (IC50) ND (EC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [8][9][10][11][12] | |
25T2-NBOMe acts as a highly potent and selective agonist of the serotonin 5-HT2 receptors.[11] Its affinities and activities at a variety of other receptors and transporters have also been described.[11]
History
25T2-NBOMe was first described in the scientific literature by at least 2012.[13]
Society and culture
Legal status
Canada
25T2-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.[14]
See also
References
- ↑ 1.0 1.1 "25X-NBOMe compounds - chemistry, pharmacology and toxicology. A comprehensive review". Critical Reviews in Toxicology 53 (1): 15–33. January 2023. doi:10.1080/10408444.2023.2194907. PMID 37115704.
- ↑ 2.0 2.1 "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicology Reports 14. June 2025. doi:10.1016/j.toxrep.2025.101890. PMID 39867514. Bibcode: 2025ToxR...1401890G.
- ↑ 3.0 3.1 "NBOMes-Highly Potent and Toxic Alternatives of LSD". Frontiers in Neuroscience 14. 2020. doi:10.3389/fnins.2020.00078. PMID 32174803.
- ↑ 4.0 4.1 "NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review". European Review for Medical and Pharmacological Sciences 19 (17): 3270–3281. September 2015. PMID 26400534. https://www.europeanreview.org/wp/wp-content/uploads/3270-3281.pdf.
- ↑ 5.0 5.1 "Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens". Neuropharmacology of New Psychoactive Substances (NPS). Curr Top Behav Neurosci. 32. 2017. 283–311. doi:10.1007/7854_2016_64. ISBN 978-3-319-52442-9.
- ↑ 6.0 6.1 "Clinical and Toxicological Profile of NBOMes: A Systematic Review". Psychosomatics 60 (2): 129–138. 2019. doi:10.1016/j.psym.2018.11.002. PMID 30606495.
- ↑ 7.0 7.1 "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". The International Journal of Neuropsychopharmacology 21 (10): 926–931. October 2018. doi:10.1093/ijnp/pyy047. PMID 29850881.
- ↑ "Kᵢ Database". 15 July 2025. https://pdspdb.unc.edu/kidb2/kidb/web/kis-results/index?KisResultsSearch%5Binput_receptors%5D=&KisResultsSearch%5Binput_sources%5D=&KisResultsSearch%5Binput_species%5D=&KisResultsSearch%5Binput_hot_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D%5B%5D=14687&KisResultsSearch%5Binput_citations%5D=&KisResultsSearch%5BsearchType%5D=&KisResultsSearch%5Bki_val_from%5D=&KisResultsSearch%5Bki_val_to%5D=&KisResultsSearch%5Bcustom_ki_val%5D=.
- ↑ Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
- ↑ "Synthesis and Structure–Activity Relationships of N -Benzyl Phenethylamines as 5-HT 2A/2C Agonists". ACS Chemical Neuroscience 5 (3): 243–249. 19 March 2014. doi:10.1021/cn400216u. ISSN 1948-7193. PMID 24397362.
- ↑ 11.0 11.1 11.2 "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology 99: 546–553. December 2015. doi:10.1016/j.neuropharm.2015.08.034. PMID 26318099. https://psilosybiini.info/paperit/Receptor%20interaction%20profiles%20of%20novel%20N-2-methoxybenzyl%20(NBOMe)%20derivatives%20of%202,5-dimethoxy-substituted%20phenethylamines%20(2C%20drugs)%20(Rickli%20et%20al.,%202015).pdf.
- ↑ "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". The Journal of Pharmacology and Experimental Therapeutics 357 (1): 134–144. April 2016. doi:10.1124/jpet.115.229765. PMID 26791601. https://d1wqtxts1xzle7.cloudfront.net/74120533/eae6c6e62565b82d46b4d111bbea0f77b9c2-libre.pdf?1635931703=&response-content-disposition=inline%3B+filename%3DIn_Vitro_Characterization_of_Psychoactiv.pdf&Expires=1746838268&Signature=Sy4fJ90yUhxs68314NxYsW5PAaNrBGePRu35WRR4PIF-3YC7Z~sLdnCn5wfqqbLg9bDEGdt~oW55ugMP3D3jgA0BoRI~~GOb0NQOwrtfUEQK1PQs1uuN9qg5Y1ct8z5NsABm44RgtukkwRMdU6fO7OlfIsQ68hOiFk129Ll7UYqldxD2f1xhE2fTTfsxSpb8cMCJzHn7-ItqLdwnAUPFK7WggDIjmY1kCnaHLwIxMwdJCAq8L6DYzSTg7pZkbR8qlou~GXbTPQt~gYpyZTJp5hgW-7V6K5wLlQ7Z2xE7B0f9wEfuc1W1QNafg125Tr-vvAe4LEGKXV58bnn1bpfWKw__&Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA.
- ↑ "Characterization of eleven 2, 5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues—part I.". Microgram Journal 9 (2): 84–109. 2012. https://www.dea.gov/sites/default/files/pr/microgram-journals/2012/mj9_84-109.pdf.
- ↑ "Controlled Drugs and Substances Act". https://laws-lois.justice.gc.ca/eng/acts/c-38.8/FullText.html.
External links
 |  |
